Switch theme
Sign up to access all valuation multiples
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
2016
35
LTM Revenue $1.2M
LTM EBITDA -$90.3M
$2.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Applied Therapeutics has a last 12-month revenue (LTM) of $1.2M and a last 12-month EBITDA of -$90.3M.
In the most recent fiscal year, Applied Therapeutics achieved revenue of $0.5M and an EBITDA of -$104M.
Applied Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Applied Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | $1.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$90.3M | XXX | -$104M | XXX | XXX | XXX |
| EBITDA Margin | -7411% | XXX | -22829% | XXX | XXX | XXX |
| EBIT | -$99.4M | XXX | -$104M | XXX | XXX | XXX |
| EBIT Margin | -8159% | XXX | -22923% | XXX | XXX | XXX |
| Net Profit | -$98.7M | XXX | -$106M | XXX | XXX | XXX |
| Net Margin | -8100% | XXX | -23214% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Applied Therapeutics's stock price is $0.
Applied Therapeutics has current market cap of $50.0M, and EV of $2.0M.
See Applied Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0M | $50.0M | XXX | XXX | XXX | XXX | $-0.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Applied Therapeutics has market cap of $50.0M and EV of $2.0M.
Applied Therapeutics's trades at 4.3x EV/Revenue multiple, and -0.0x EV/EBITDA.
Equity research analysts estimate Applied Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Applied Therapeutics has a P/E ratio of -0.5x.
See valuation multiples for Applied Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50.0M | XXX | $50.0M | XXX | XXX | XXX |
| EV (current) | $2.0M | XXX | $2.0M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApplied Therapeutics's last 12 month revenue growth is 996%
Applied Therapeutics's revenue per employee in the last FY averaged $13K, while opex per employee averaged $3.0M for the same period.
Applied Therapeutics's rule of 40 is 354% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Applied Therapeutics's rule of X is -4920% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Applied Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 996% | XXX | 699% | XXX | XXX | XXX |
| EBITDA Margin | -7411% | XXX | -22829% | XXX | XXX | XXX |
| EBITDA Growth | -33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 354% | XXX | -21833% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4920% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $13K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10713% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23023% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Applied Therapeutics acquired XXX companies to date.
Last acquisition by Applied Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Applied Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Applied Therapeutics founded? | Applied Therapeutics was founded in 2016. |
| Where is Applied Therapeutics headquartered? | Applied Therapeutics is headquartered in United States of America. |
| How many employees does Applied Therapeutics have? | As of today, Applied Therapeutics has 35 employees. |
| Who is the CEO of Applied Therapeutics? | Applied Therapeutics's CEO is Mr. Les Funtleyder. |
| Is Applied Therapeutics publicy listed? | Yes, Applied Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Applied Therapeutics? | Applied Therapeutics trades under APLT ticker. |
| When did Applied Therapeutics go public? | Applied Therapeutics went public in 2019. |
| Who are competitors of Applied Therapeutics? | Similar companies to Applied Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Applied Therapeutics? | Applied Therapeutics's current market cap is $50.0M |
| What is the current revenue of Applied Therapeutics? | Applied Therapeutics's last 12 months revenue is $1.2M. |
| What is the current revenue growth of Applied Therapeutics? | Applied Therapeutics revenue growth (NTM/LTM) is 996%. |
| What is the current EV/Revenue multiple of Applied Therapeutics? | Current revenue multiple of Applied Therapeutics is 1.6x. |
| Is Applied Therapeutics profitable? | Yes, Applied Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Applied Therapeutics? | Applied Therapeutics's last 12 months EBITDA is -$90.3M. |
| What is Applied Therapeutics's EBITDA margin? | Applied Therapeutics's last 12 months EBITDA margin is -7411%. |
| What is the current EV/EBITDA multiple of Applied Therapeutics? | Current EBITDA multiple of Applied Therapeutics is -0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
